Vonopazan +Amoxicillin
PreclinicalSmall molecule
Vonopazan +Amoxicillin is one of 15 small molecule programs targeting Helicobacter Pylori. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Helicobacter Pylori
#DrugCompanyPhaseTrials
1Biaxin
AbbVieApproved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Nexium
DDexcel Pharma Technologies Ltd.
Approved
Potassium Citrate
MMission Pharmacal
Approved
Flagyl
DDePuy Orthopaedics
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Alinia
RRomark Laboratories L.C.
Phase 3
Keverprazan
NNanjing First Hospital, Nanjing Medical University
Phase 3
Proton Pump Inhibitor
AAVM Biotechnology Inc
Phase 3
PYTEST 14c-Urea Breath Test
UUniversity of Miami
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Vonopazan +Amoxicillin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SShanghai Changzheng Hospital